Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVO – Novo Nordisk A/S

Novo Nordisk A/S
NVO
$48.19
Name : Novo Nordisk A/S
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $213,983,363,072.00
EPSttm : 3.59
finviz dynamic chart for NVO
Novo Nordisk A/S
$48.19
2.38%
$1.12

Float Short %

0.7

Margin Of Safety %

44

Put/Call OI Ratio

0.81

EPS Next Q Diff

5.32

EPS Last/This Y

EPS This/Next Y

2.94

Price

48.19

Target Price

81.59

Analyst Recom

2.19

Performance Q

-26.54

Relative Volume

2.75

Beta

0.63

Ticker: NVO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04NVO69.140.930.82556778
2025-07-07NVO69.310.920.41536301
2025-07-08NVO69.640.900.44546835
2025-07-09NVO69.710.910.35552241
2025-07-10NVO71.020.911.49555881
2025-07-11NVO68.870.950.49570868
2025-07-14NVO68.940.920.62550941
2025-07-15NVO67.390.920.63558002
2025-07-16NVO67.060.921.50561751
2025-07-17NVO65.320.930.51568864
2025-07-18NVO64.310.892.43573939
2025-07-21NVO64.960.920.46524718
2025-07-22NVO66.80.920.62538464
2025-07-23NVO70.020.920.46546137
2025-07-24NVO70.730.891.31570564
2025-07-25NVO71.720.930.39587060
2025-07-28NVO68.990.900.77568017
2025-07-29NVO54.020.900.70575125
2025-07-30NVO50.090.870.58747757
2025-07-31NVO47.090.830.85885071
2025-08-01NVO48.150.810.421011804
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04NVO69.1734.61562.626.02
2025-07-07NVO69.3134.61818.126.02
2025-07-08NVO69.6434.61755.826.02
2025-07-09NVO69.6934.61519.026.02
2025-07-10NVO71.0134.62295.726.02
2025-07-11NVO68.9334.61619.526.02
2025-07-14NVO68.9434.61832.226.02
2025-07-15NVO67.2234.61053.926.02
2025-07-16NVO67.0734.61516.326.02
2025-07-17NVO65.2934.6899.726.02
2025-07-18NVO64.3134.61058.626.02
2025-07-21NVO64.9434.61771.526.02
2025-07-22NVO66.7734.62613.626.02
2025-07-23NVO70.0334.63003.726.02
2025-07-24NVO70.7334.62217.626.02
2025-07-25NVO71.7034.62376.626.02
2025-07-28NVO68.9733.21035.426.04
2025-07-29NVO53.9433.2-3688.726.04
2025-07-30NVO50.0333.2-136.426.04
2025-07-31NVO47.0733.0-1091.825.07
2025-08-01NVO48.1933.0-629.025.07
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04NVO0-4.380.79
2025-07-07NVO0-3.900.79
2025-07-08NVO0-3.900.79
2025-07-09NVO0-3.900.79
2025-07-10NVO0-3.900.79
2025-07-11NVO0-3.900.76
2025-07-14NVO0-4.250.76
2025-07-15NVO0-4.250.76
2025-07-16NVO0-4.250.76
2025-07-17NVO0-4.250.76
2025-07-18NVO0-4.250.76
2025-07-21NVO0-4.380.76
2025-07-22NVO0-4.380.76
2025-07-23NVO0-4.380.76
2025-07-24NVO0-4.380.76
2025-07-25NVO0-4.380.70
2025-07-28NVO0-5.270.70
2025-07-29NVO0-5.270.70
2025-07-30NVO0-5.270.70
2025-07-31NVO0-5.270.70
2025-08-01NVO0-5.270.70
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.92

Avg. EPS Est. Current Quarter

5.96

Avg. EPS Est. Next Quarter

6.24

Insider Transactions

Institutional Transactions

-5.27

Beta

0.63

Average Sales Estimate Current Quarter

76933

Average Sales Estimate Next Quarter

78904

Fair Value

69.55

Quality Score

98

Growth Score

96

Sentiment Score

3

Actual DrawDown %

67.5

Max Drawdown 5-Year %

-68

Target Price

81.59

P/E

14.29

Forward P/E

11.01

PEG

0.94

P/S

3.72

P/B

10.67

P/Free Cash Flow

11.36

EPS

3.37

Average EPS Est. Cur. Y​

25.07

EPS Next Y. (Est.)

28.01

Target Price Estimates Raised

Target Price Estimates Lowered

4

Profit Margin

34.52

Relative Volume

2.75

Return on Equity vs Sector %

51.8

Return on Equity vs Industry %

43.5

EPS 1 7Days Diff

-1

EPS 1 30Days Diff

-1.06

EBIT Estimation

-629
Novo Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 77406
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading